News

We are pleased to announce the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10^th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.

The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, along with the prevalence and incidence of comorbidities in patients with the disease.

Read the press release, here.

To find out more about the GPP registry, including some information on some of the variables we collect, visit corevitas.com/gpp-generalized-pustular-psoriasis-registry/

WALTHAM, Mass –(December 20, 2023) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of CorEvidence, a proprietary cloud-based data lake platform optimizing pharmacovigilance case processing and safety data management processes. The new platform enhances CorEvitas clinical research registries offered by Thermo Fisher’s PPD clinical research business.

CorEvidence’s first application supports enhanced pharmacovigilance workflow and deliverable management. It is designed to handle multiple data sources and streamline coding, classification and reporting of adverse events and safety events of interest for committed post-authorization safety studies. The platform supports a full range of pharmacovigilance deliverables with efficient, traceable, auditable, scalable and compliant safety management for customer safety commitments using data collected through CorEvitas syndicated registries.

“I am excited to see us deliver fit-for-purpose, highly impactful solutions to some of our most challenging and complex pharmacovigilance business needs,” said Christine Barr, vice president of pharmacovigilance, CorEvitas. “We look forward to the positive impact this system will have on our customers and, most importantly, the well-being of the patients and our medical communities who depend on timely availability of real-world evidence and ongoing benefit/risk assessment activities to inform the safe use of pharmaceutical products.”

Thermo Fisher acquired CorEvitas, a leading provider of gold-standard real-world evidence solutions, in August 2023. CorEvitas services include 12 registries, including nine autoimmune and inflammatory syndicated registries, and a data intelligence platform that builds and scales clinical registries across multiple therapeutic areas to gather structured patient clinical data spanning 400 investigator sites and over 100,000 patients followed longitudinally. The CorEvitas model is being leveraged to satisfy regulatory requirements for more than 15 long-term post-authorization safety studies across eight disease indications. To learn more about CorEvidence, email info@corevitas.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media Contact Information:

Nadine Maeser, nadine.maesar@ppd.com

Patient pathway mapping tool developed with Biogen wins BOBI award

Waltham, MA (July 3, 2023) – CorEvitas, LLC, the gold-standard provider of real-world evidence solutions for the life sciences industry, today announced that it has received the 2023 BOBI (Best of Business Intelligence) Award for Best Use of Innovation from the British Healthcare Business Intelligence Association (BHBIA) at their annual awards gala on June 12, 2023. The BOBI Awards recognize excellence across the healthcare business intelligence spectrum.

CorEvitas was recognized for its innovative Vantage Simulations solution, a patient pathway mapping and modeling tool. This award recognized the irritable bowel disease (IBD) pathway simulation model developed by CorEvitas and Biogen to support infusion clinics struggling with a high patient load, by identifying the resources and equipment required for a robust, sustainable infusion service. Creating transparency around the patient pathway, then adding real-world data and configurable local inputs, facilitates informed and evidence-driven planning by clinicians and commissioners to optimize services and improve patient outcomes.

“COVID-19 brought shortcomings and inequalities within the National Health System (NHS) sharply into focus, while the introduction of Integrated Care Systems (ICSs) requires clinical pathways to be restructured to realize targets and service efficiencies,” emphasizedParita Patel, CorEvitas Product Director. “The need for digital tools to support decision-making is pressing, and our user-friendly, real-world data-driven modeling tool transforms the approach to service redesign, enabling confident and quick decision-making by healthcare providers and practitioners.”

IBD has a profound impact on a patient’s life, requiring lifelong expert care and treatment. One in every 123 people living in the UK suffers from Crohn’s disease or colitis, increasing to one in every 67 people over 70.5 years of age. There is currently no cure for either disease, and the financial impact on the NHS for IBD care is comparable to conditions like heart disease and cancer. The 15 million people in England with long-term conditions like IBD have the greatest healthcare needs of the population.

Biogen and CorEvitas are delighted to be recognized by the BHBIA and BOBI Awards for their innovative IBD pathway simulation model. The BOBI Awards team commented,

“The judges were impressed with the wide-reaching impact, including positive impact on the NHS…the approach was really innovative.”

In addition to Parita Patel, applicants for this award included Eva Fuchs, CorEvitas Solutions Specialist; Ivan Rickard, Biogen National Market Access Manager, UK/Ire Biosimilars; and Simon Keady, Biogen EU Market Access Lead – Biosimilars.

To learn more about Vantage Simulations, visit www.corevitas.com/vantage/simulations. For additional information on CorEvitas’ Vantage real-world data business intelligence solutions, visit www.corevitas.com/vantage.

About CorEvitas

CorEvitas is a science-led, real-world data intelligence company. Using syndicated registry data and analytic services to understand the real-world safety, effectiveness, and patient experience of therapeutics, CorEvitas provides the life sciences industry with the objective data and clinical insights to demonstrate the value of their products to clinicians, patients, payers, and regulators. The company operates nine major autoimmune and inflammatory registries across the US, Canada, and Japan, collecting data from over 400 participating investigator sites, including the collection of biosamples linked to deep clinical data. CorEvitas recently expanded its services to include Pregnancy Registries through the acquisition of Pregistry, LLC. CorEvitas also conducts client-sponsored registries through its Patient Powered Registries business, employing a transformative patient-focused registry model to support research needs for patient-centered outcomes across all therapeutic areas. The company’s regulatory-grade registry data is complemented by its Patient Experience business, supporting evidence-based patient engagement initiatives across the product lifecycle, as well as its Specialty EMR Data business and retinal data set. CorEvitas is headquartered in Waltham, MA and is a portfolio company of Audax Private Equity. www.corevitas.com

CONTACT INFORMATION:

CorEvitas, LLC
Karen Krewson
+1(508) 408-5435
kkrewson@corevitas.com